Dilated Cardiomyopathy (DCM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Dilated Cardiomyopathy (DCM) Market Outlook

Thelansis’s “Dilated Cardiomyopathy (DCM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dilated Cardiomyopathy (DCM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dilated Cardiomyopathy (DCM) Overview

Dilated cardiomyopathy (DCM) is a pathological condition of the heart characterized by the dilation and enlargement of one or both ventricles, along with impaired contractility, as defined by a left ventricular ejection fraction (LVEF) of less than 40%. The condition can be classified as primary or secondary, with primary DCM being of idiopathic origin and diagnosed after excluding secondary causes. Patients with DCM typically have systolic dysfunction and may or may not exhibit overt symptoms of heart failure. DCM is often progressive, leading to heart failure and death. Without a transplant, survival rates for patients with DCM are poor. The etiology of DCM is diverse, with the most common cause being idiopathy, and may also have a familial or genetic predisposition. Secondary causes include infectious myocarditis, ischemic disease, hypertension, medication-induced alcohol abuse, HIV, peripartum cardiomyopathy, or infiltrative disease. The New York Heart Association (NYHA) classification of heart failure is often used to assess the severity of DCM. It includes four stages: Stage A (at-risk individuals), Stage B (asymptomatic left ventricular systolic dysfunction), Stage C (symptomatic heart failure), and Stage D (refractory end-stage heart failure). Overall, the prognosis for patients with DCM is guarded, with most patients eventually developing chronic heart failure. Negative prognostic factors include advanced NYHA classification, male sex, severe heart failure, and renal failure. Individuals with symptoms at rest and cannot exercise usually have the poorest prognosis. Optimal medical therapy can improve the quality of life for patients with mild heart failure.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Dilated Cardiomyopathy (DCM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034